Display options
Cite
St Helen G, Ross KC, Dempsey DA, et al. Nicotine Delivery and Vaping Behavior During . Tob Regul Sci. 2016;2(4):363-376doi: 10.18001/TRS.2.4.8.
St Helen, G., Ross, K. C., Dempsey, D. A., Havel, C. M., Jacob, P., & Benowitz, N. L. (2016). Nicotine Delivery and Vaping Behavior During . Tobacco regulatory science, 2(4), 363-376. https://doi.org/10.18001/TRS.2.4.8
St Helen, Gideon, et al. "Nicotine Delivery and Vaping Behavior During ." Tobacco regulatory science vol. 2,4 (2016): 363-376. doi: https://doi.org/10.18001/TRS.2.4.8
St Helen G, Ross KC, Dempsey DA, Havel CM, Jacob P, Benowitz NL. Nicotine Delivery and Vaping Behavior During . Tob Regul Sci. 2016 Oct;2(4):363-376. doi: 10.18001/TRS.2.4.8. PMID: 28393086; PMCID: PMC5381821.
Copy Download .nbib Format: NLM
Share it on

Tob Regul Sci. 2016 Oct;2(4):363-376. doi: 10.18001/TRS.2.4.8.

Nicotine Delivery and Vaping Behavior During .

Tobacco regulatory science

Gideon St Helen, Kathryn C Ross, Delia A Dempsey, Christopher M Havel, Peyton Jacob, Neal L Benowitz

Affiliations

  1. Assistant Professor, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.
  2. Postdoctoral fellow, Center for Tobacco Control Research and Education, University of California, San Francisco, CA.
  3. Physician, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.
  4. Chemist, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.
  5. Research Chemist, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.
  6. Professor, Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, University of California, San Francisco, CA.

PMID: 28393086 PMCID: PMC5381821 DOI: 10.18001/TRS.2.4.8

Abstract

OBJECTIVE: To characterize vaping behavior and nicotine intake during

METHODS: Thirteen adult e-cigarette users had 90 minutes of videotaped

RESULTS: Average puff duration and interpuff interval were 3.5±1.4 seconds (±SD) and 118±141 seconds, respectively. 12% of puffs were unclustered puffs while 43%, 28%, and 17% were clustered in groups of 2-5, 6-10, and >10 puffs, respectively. On average, 4.0±3.3 mg of nicotine was inhaled; the maximum plasma nicotine concentration (C

CONCLUSION: Vaping patterns differ from cigarette smoking. Plasma nicotine levels were consistent with intermittent dosing of nicotine from e-cigarettes compared to the more bolus dosing from cigarettes. Differences in delivery patterns and peak levels of nicotine achieved could influence the addictiveness of e-cigarettes compared to conventional cigarettes.

Keywords: addictive potential; e-cigarettes; nicotine pharmacokinetics; vaping patterns; vaping topography

Conflict of interest statement

Conflict of Interest Statement Dr. Neal Benowitz serves as a consultant to several pharmaceutical companies that market smoking cessation medications and has served as a paid expert witness in litigat

References

  1. Pharmacol Biochem Behav. 1999 Jan;62(1):165-72 - PubMed
  2. Addict Behav. 1994 Jul-Aug;19(4):411-27 - PubMed
  3. Biol Mass Spectrom. 1991 May;20(5):247-52 - PubMed
  4. Nicotine Tob Res. 2001 Feb;3(1):7-16 - PubMed
  5. Addict Behav. 2015 Sep;48:1-4 - PubMed
  6. Addiction. 2012 Aug;107(8):1493-500 - PubMed
  7. Drug Alcohol Depend. 2015 Mar 1;148:102-8 - PubMed
  8. Tob Control. 2010 Apr;19(2):98-103 - PubMed
  9. Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):154-7 - PubMed
  10. Nicotine Tob Res. 2010 Aug;12(8):855-9 - PubMed
  11. Pharmacol Rev. 2005 Mar;57(1):79-115 - PubMed
  12. Arch Gen Psychiatry. 1986 Mar;43(3):289-94 - PubMed
  13. PLoS One. 2015 Feb 09;10(2):e0117222 - PubMed
  14. Nicotine Tob Res. 2016 May;18(5):564-71 - PubMed
  15. J Chromatogr. 1981 Jan 2;222(1):61-70 - PubMed
  16. Nicotine Tob Res. 2015 Feb;17(2):219-27 - PubMed
  17. Lancet Respir Med. 2016 Feb;4(2):116-28 - PubMed
  18. Adv Dent Res. 1997 Sep;11(3):330-5 - PubMed
  19. Tob Induc Dis. 2014 Oct 10;12(1):17 - PubMed
  20. Nicotine Tob Res. 2015 Feb;17(2):150-7 - PubMed
  21. MMWR Morb Mortal Wkly Rep. 2015 Apr 17;64(14):381-5 - PubMed
  22. Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):936-43 - PubMed
  23. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1370-5 - PubMed
  24. Psychopharmacology (Berl). 2014 Jan;231(2):401-7 - PubMed
  25. Nicotine Tob Res. 2015 Feb;17(2):142-9 - PubMed
  26. Nicotine Tob Res. 2013 Jan;15(1):267-70 - PubMed
  27. Sci Rep. 2014 Feb 26;4:4133 - PubMed
  28. Lancet. 2006 Mar 4;367(9512):781-7 - PubMed
  29. Clin Pharmacol Ther. 2006 Dec;80(6):703-14 - PubMed
  30. Addiction. 2016 Mar;111(3):535-44 - PubMed
  31. Nicotine Tob Res. 2013 Jan;15(1):158-66 - PubMed
  32. Tob Control. 2013 Mar;22(2):103-6 - PubMed
  33. J Consult Clin Psychol. 1993 Oct;61(5):743-50 - PubMed
  34. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1800-4 - PubMed
  35. Int J Environ Res Public Health. 2013 Jun 18;10(6):2500-14 - PubMed
  36. Nicotine Tob Res. 2009 Jul;11(7):896-903 - PubMed
  37. Tob Control. 2014 May;23 Suppl 2:ii23-9 - PubMed
  38. Addict Behav. 1988;13(1):91-5 - PubMed
  39. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):468-71 - PubMed
  40. PLoS One. 2015 Jun 08;10(6):e0129296 - PubMed

Publication Types

Grant support